GORE VIABAHN FORTEGRA Venous Stent
W. L. Gore & Associates, Inc. · Decision date Dec 19, 2025
What did the FDA approve?
FDA records P250017 as an original PMA application. The recorded decision is approval, dated Dec 19, 2025.
FDA approval order statement
The GORE VIABAHN FORTEGRA Venous Stent is indicated for use in the treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 19, 2025
Regulatory record facts
- Identifier
- P250017
- Regulatory pathway
- Premarket approval application
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QTL
- Decision code
- APPR
- Decision date
- Dec 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, vena cava.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QTL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250017 received
Application receipt date recorded by FDA.
P250017 · FDA decision
APPR
P250017/S002 · Related supplement
GORE VIABAHN FORTEGRA Venous Stent
P250017/S001 · Related supplement
GORE VIABAHN FORTEGRA Venous Stent
P250017/S003 · Related supplement
GORE VIABAHN FORTEGRA Venous Stent
Timeline entries are records held by MedtechLedger for P250017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250017
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
GORE VIABAHN FORTEGRA Venous StentP250017/S002 | W. L. Gore & Associates, Inc. | PMA supplement | Mar 6, 2026 | FDA |
GORE VIABAHN FORTEGRA Venous StentP250017/S001 | W. L. Gore & Associates, Inc. | PMA supplement | Apr 7, 2026 | FDA |
GORE VIABAHN FORTEGRA Venous StentP250017/S003 | W. L. Gore & Associates, Inc. | PMA supplement | Apr 30, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1505 N Fourth St., Flagstaff, AZ, 86004
Sources and methodology
- Original FDA record: P250017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

